Indian Drug Pricing Authority Allows Increases In Six Bulk Drugs
This article was originally published in PharmAsia News
Executive Summary
India's National Pharmaceutical Pricing Authority has increased the cap on prices that can be charged for six bulk drugs. The increase covers cefataxime sodium, metronidazole, metronidazole benzoate, parachlorometaxylenol, ranitidine HCI and vitamen E acetate. Effective 15 days after official notification, drug makers are allowed to increase the prices of the drugs within a range of 3 percent to 12 percent. Makers of drugs using those ingredients are allowed to increase their own prices by about 8 percent if the price of the bulk drug rises by 12 percent. (Click here for more
You may also be interested in...
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.
BMS Has A Strong Pipeline, But Access Challenges Remain
Bristol Myers Squibb’s head of major markets, Monica Shaw, wants to improve patients’ access to lifesaving therapies. And the group has several new products ready to roll.
Novartis Hires Ex-BMS Chief As It Pursues US Growth Strategy
The Swiss pharma company is looking to tap into the experience of ex-BMS leader Giovanni Caforio to help further it US-first commercial strategy.